Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 32, 2015 - Issue 1
Submit an article Journal homepage
563
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Vincristine and Irinotecan in Children with Relapsed Hepatoblastoma: A Single-Institution Experience

Yu-tong ZhangDepartment of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, China
,
Li-hua FengDepartment of Obstetrics and Gynecology, the First Hospital of Jilin University, Changchun, Jilin, China
,
Xiao-dan ZhongDepartment of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, China
,
Li-zhe WangDepartment of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, China
&
Jian ChangDepartment of Pediatric Hematology and Oncology, the First Hospital of Jilin University, Changchun, Jilin, ChinaCorrespondence[email protected]
Pages 18-25 | Received 19 Oct 2013, Accepted 26 Mar 2014, Published online: 22 May 2014

REFFERENCES

  • Perilongo G, Shafford EA. Liver tumors. Eur J Cancer. 1999;35:953–959.
  • Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int. 2011;27:1–8.
  • Zsiros J, Maibach R, Schafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28:2584–2590.
  • Tiao GM, Bobey N, Allen S, et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr Surg. 2005;146:204–211.
  • Bomgaars LR, Berstein M, Krailo M, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007;25:4622–4627.
  • Qayed M, Powell C, Morgan ER, et al. Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer. 2010;54:761–763.
  • Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol. 2003;21:3844–3852.
  • Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblatoma: a Children's Oncology Group Study. J Clin Oncol. 2011;29:208–213.
  • Zsíros J, Brugières L, Brock P, et al. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma–a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur J Cancer. 2012;48:3456–3464.
  • Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1). Gan To Kagaku Ryoho. 2009;36:2495–2501.
  • NCI. CTCAE. http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 17 May 2010.
  • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.
  • Wald NJ, Rudnicka AR, Bestwick JP. Sequential and contingent prenatal screening for Down syndrome. Prenat Diagn. 2006;26(9):769–777.
  • Palmer RD, Williams DM. Dramatic response of multiply relapsed hepatoblastoma to irinotecan. Med Pediatr Oncol. 2003;41:78–80.
  • Venkatramani R, Furman WL, Fuchs J, et al. Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs. 2012;14:221–232.
  • Katzenstein HM, Rigsby C, Shaw PH, et al. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol. 2002;24:751–755.
  • Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Ocol. 2006;24:5271–5276.
  • Blaney S, Berg S, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a pediatric Oncology Group Study. Clin Cancer Res. 2001;7:3237.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.